Get the Stockscreener App
81.88
4.45%
3.49
Pre-market:
79.40
-2.48
-3.03%
Illumina Inc stock is traded at $81.88, with a volume of 1.90M.
It is up +4.45% in the last 24 hours and down -7.73% over the past month.
See More
Previous Close:
$78.39
Open:
$78.27
24h Volume:
1.90M
Relative Volume:
0.83
Market Cap:
$12.42B
Revenue:
$4.39B
Net Income/Loss:
$-1.58B
P/E Ratio:
-8.2209
EPS:
-9.96
Net Cash Flow:
$546.00M
1W Performance:
-1.15%
1M Performance:
-7.73%
6M Performance:
-41.10%
1Y Performance:
-36.29%
1-Day Range:
$77.99
$82.76
1-Week Range:
$77.54
$83.09
52-Week Range:
$77.54
$156.66
Illumina Inc Stock (ILMN) Company Profile
Name
Illumina Inc
Sector
Industry
Phone
(858) 202-4500
Address
5200 ILLUMINA WAY, SAN DIEGO, CA
Compare ILMN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ILMN
Illumina Inc
|
81.88 | 12.42B | 4.39B | -1.58B | 546.00M | -9.96 |
|
TMO
Thermo Fisher Scientific Inc
|
489.06 | 182.21B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
205.16 | 143.37B | 23.88B | 3.90B | 5.30B | 5.28 |
|
IDXX
Idexx Laboratories Inc
|
426.25 | 33.92B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
115.99 | 33.08B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
174.37 | 30.19B | 15.41B | 1.37B | 2.11B | 7.50 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-04-25 | Reiterated | Citigroup | Neutral |
| Feb-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Feb-10-25 | Downgrade | Barclays | Equal Weight → Underweight |
| Feb-07-25 | Downgrade | TD Cowen | Buy → Hold |
| Dec-11-24 | Downgrade | Citigroup | Buy → Neutral |
| Nov-12-24 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-24 | Upgrade | HSBC Securities | Hold → Buy |
| Aug-28-24 | Upgrade | Argus | Hold → Buy |
| Aug-16-24 | Upgrade | Daiwa Securities | Neutral → Buy |
| Aug-14-24 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-14-24 | Upgrade | TD Cowen | Hold → Buy |
| Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-16-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Dec-18-23 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Dec-15-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-11-23 | Upgrade | Citigroup | Sell → Neutral |
| Nov-10-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Sep-28-23 | Initiated | Bernstein | Underperform |
| Jul-05-23 | Resumed | JP Morgan | Neutral |
| Jan-25-23 | Downgrade | Argus | Buy → Hold |
| Jan-05-23 | Initiated | Scotiabank | Sector Perform |
| Dec-12-22 | Downgrade | Citigroup | Neutral → Sell |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-04-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-28-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| Jul-13-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-18-22 | Upgrade | Stifel | Hold → Buy |
| Jan-11-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-07-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-19-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-01-21 | Upgrade | Evercore ISI | Underperform → In-line |
| Mar-31-21 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Mar-31-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-21 | Initiated | Barclays | Underweight |
| Dec-22-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-17-20 | Upgrade | BTIG Research | Neutral → Buy |
| Oct-13-20 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Sep-29-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-22-20 | Downgrade | Stifel | Buy → Hold |
| Sep-22-20 | Downgrade | UBS | Buy → Neutral |
| Sep-21-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-21-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-07-20 | Downgrade | Evercore ISI | In-line → Underperform |
| Aug-07-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-20 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-24-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-15-19 | Initiated | Stifel | Buy |
| Oct-25-19 | Initiated | Guggenheim | Buy |
View All
Illumina Inc Stock (ILMN) Latest News
How Illumina employees step up, reach out, and give back - Illumina
Characterizing alveolar dysregulation in pulmonary fibrosis using Illumina Spatial Technology - Illumina
Personalized Medicine Market Growth Trends 2025-2033: Transition to Customized Medical Care, Developments in Bioinformatics and Genomics, Growing Prevalence of Chronic Diseases - GlobeNewswire Inc.
Here's How Much $1000 Invested In Illumina 20 Years Ago Would Be Worth Today - Benzinga
Argus cuts Illumina target, sees buying opportunity - Yahoo Finance
Illumina careers: Expanding access to NGS in emerging markets - Illumina
The Zacks Analyst Blog Highlights Illumina, BEAM, Twist Bioscience, Wave Life Sciences and CRISPR Therapeutics - Nasdaq
Corvex’s Meister joins the board at Illumina. Here’s how he can create value for shareholders - MSN
Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Artisan Partners Limited Partnership - MarketBeat
Corvex's Meister joins the board at Illumina. Here's how he can create value for shareholders - NBC Los Angeles
Illumina stock hits 52-week low at $80.18 amid market challenges By Investing.com - Investing.com South Africa
Illumina stock hits 52-week low at $80.18 amid market challenges - Investing.com India
New in the lab: Test driving the MiSeq i100 Plus - Illumina
Analyst recommendations: Illumina, Boeing, Next, Walmart, Applovin.... - MarketScreener
AI In Genomics Market to Reach $9.8 Billion, Globally, by 2031 - openPR
NGS Sample Preparation Market Techniques Reshaping Genomic - openPR
Cathie Wood’s ARK trims Illumina, exits Repare Therapeutics stock By Investing.com - Investing.com South Africa
Cathie Wood’s ARK trims Illumina, exits Repare Therapeutics stock - Investing.com
Illumina Adds Activist to Board, Names Former FDA Chief as Chair - MSN
May 9th Options Now Available For Illumina (ILMN) - Nasdaq
Is Illumina Undervalued After An 83% Drop In Its Stock Price? (NASDAQ:ILMN) - Seeking Alpha
Illumina is Now Oversold (ILMN) - Nasdaq
Canaccord maintains Illumina stock hold with $115 target By Investing.com - Investing.com UK
Activist investor Keith Meister to join Illumina's board - Reuters
Activist Investors Seize More Control of Illumina Amid Weakness - Markets Insider
Canaccord holds Illumina stock with $115 target amid board changes By Investing.com - Investing.com UK
Cintas, UPS, Illumina: Market Minute - Yahoo Finance
Illumina rises after board revamp - MSN
Illumina stock rises after board revamp (ILMN:NASDAQ) - Seeking Alpha
Activist Investor Meister to Join Illumina’s Board - WSJ
Activist investor Keith Meister to join Illumina’s board, WSJ reports - 1470 & 100.3 WMBD
Illumina Names Scott Gottlied as Non-Executive Board Chair; Corvex's Keith Meister Joins Board - MarketScreener
Illumina Board Of Directors Elects Dr. Scott Gottlieb Chair, Keith Meister To Join Board Of Directors - MarketScreener
Illumina Board of Directors elects Dr. Scott Gottlieb Chair, Keith Meister to join Board of Directors - PR Newswire
Activist investor Keith Meister to join Illumina's board, WSJ reports - MSN
Illumina shares rise on WSJ report activist investor Meister will join board By Investing.com - Investing.com UK
Activist investor Meister to join Illumina's board, WSJ reports - MarketScreener
Activist Investor Keith Meister Will Join The Board Of Directors Of Illumina- WSJ - MarketScreener
Single Cell Genome Sequencing Market Detailed In New Research - openPR
High End Cellomics Market Set to Witness Significant Growth - openPR
Scaling the genomics lab for the data deluge - Illumina
Illumina CIO Carissa Rollins to retire in April By Investing.com - Investing.com Australia
Illumina CIO Carissa Rollins to retire in April - Investing.com
Interrogating challenging genomic regions provides new answers for patients - Illumina
Unlocking a world of complete biological understanding - Illumina
Is Illumina, Inc. (ILMN) the Best Diagnostics Stock to Invest in Right Now? - Insider Monkey
Illumina's AGD Project Completes 250,000 Whole Genomes: Stock to Gain? - Yahoo Finance
Illumina Inc Stock (ILMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.78%
1.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):